二甲双胍对糖代谢异常的冠心病患者PAC-1表达的影响及与预后关系的研究  

The study of the influence to PAC-1 and relationship with end of metformin treatment on patients with CHD by IGT or IFG

作　　者：梁海峰[1] 边永玲 

机构地区：[1]河北北方学院附属第一医院心血管内科,张家口075000 [2]河北北方学院附属第一医院微循环研究所,张家口075000

出　　处：《中国现代药物应用》2008年第11期4-6,共3页Chinese Journal of Modern Drug Application

摘　　要：目的了解二甲双胍对糖代谢异常(IFG/IGT)的冠心病患者血小板活性标志物PAC-1表达的影响及与预后的关系。方法将符合入选标准的糖代谢异常的冠心病患者82例,随机分为A组:冠心病二级预防治疗组(n=42);B组:冠心病二级预防+二甲双胍组(n=40,二甲双胍0.5g,3次/d),同时以健康人群(n=35)做对照。随访6个月,治疗前后分别测空腹血糖(GLU)、口服葡萄糖耐量试验(OGTT)及PAC-1。结果AB两组服药前PAC-1水平高于健康对照组(P<0.05),服药1周后B组患者治疗后PAC-1水平较A组明显降低(P<0.05),但仍然高于健康对照组。6个月B组临床观察终点事件的发生率(12.8%,5/36)显著低于A组(25.6%,10/39,P<0.05)。结论早期服用二甲双胍可以在一定程度上抑制糖代谢异常的冠心病患者的PAC-1的表达,改善冠心病患者的预后。Objective To study the influence to PAC-1 and relationship with end of metformin treatment on patients with CHD by IGT or IFG. Methods 82 Patients with IFG or IGT and CHD were randomized in two groups. Group A： only received standard CHD therapy without mefformin. Group B： received oral metformin on basis of standard CHD therapy. Contrasts to health group, both groups were followed for six months. GLU, OGTr and PAC-1 were evaluated before treatment and a week after treatment Results PAC-1 were significantly higher in group A and B than health group before treatment （ P 〈 0. 05 ）. PAC-1 in group B was lower than group A in one week after treatment （ P 〈 0. 05 ）. The events after treatment were significantly lower in groupB than those in group A （ 12.8% VS 25.6% ）. Conclusion Mefformin can decrease the PAC-1 in patients with CHD by IFG or IGT. and change the end of CHD.

关 键 词：二甲双胍 糖耐量异常 空腹血糖受损 冠心病 糖蛋白ⅡbⅢa 流式细胞术 

分 类 号：R541.4[医药卫生—心血管疾病] R446.1[医药卫生—内科学]